1-20 of 36
Li Zhang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment

Aparna R. Parikh, Bryant H. Chee, Jill Tsai, Thereasa A. Rich, Kristin S. Price, Sonia A. Patel, Li Zhang, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, Joy X. Jarnagin, Victoria M. Raymond, Carlos U. Corvera, Kenzo Hirose, Eric K. Nakakura, Ryan B. Corcoran, Katherine Van Loon, Chloe E. Atreya
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (14): 2964–2973.
https://doi.org/10.1158/1078-0432.CCR-23-3660
Published: 15 July 2024
View article titled, Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment
Open the PDF for Minimal Residual Disease using a Plasma-Only Circulating Tumor DNA Assay to Predict Recurrence of Metastatic Colorectal Cancer Following Curative Intent Treatment in another window
Includes: Supplementary data
Journal Articles

Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC

Lanlan Pang, Yihua Huang, Weitao Zhuang, Yaxiong Zhang, Jun Liao, Yue Hao, Feng Hao, Guoqian Wang, Ze-xin Chase Chen, Yu Zhu, Mengzhen Li, Zhengbo Song, Bo Peng Deng, Jing Li, Li Zhang, Wenfeng Fang
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (12): 2636–2646.
https://doi.org/10.1158/1078-0432.CCR-23-3302
Published: 14 June 2024
View article titled, Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC
Open the PDF for Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC in another window
Includes: Supplementary data
Journal Articles

Germline USP36 Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan, Xi Chen, Yuru Wei, Fei Wang, Wen Xie, Youhao Chen, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Xiaoxu Zhang, Shu Liu, Wei Zhuang, Min Huang, Xueding Wang, Li Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (7): 1382–1396.
https://doi.org/10.1158/1078-0432.CCR-23-2357
Published: 01 April 2024
View article titled, Germline <em>USP36</em> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer
Open the PDF for Germline <em>USP36</em> Mutation Confers Resistance to EGFR-TKIs by Upregulating MLLT3 Expression in Patients with Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA

Li-Peng Liu, Su-Yu Zong, Ao-Li Zhang, Yuan-Yuan Ren, Ben-Quan Qi, Li-Xian Chang, Wen-Yu Yang, Xiao-Juan Chen, Yu-Mei Chen, Li Zhang, Yao Zou, Ye Guo, Ying-Chi Zhang, Min Ruan, Xiao-Fan Zhu
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (6): 1143–1151.
https://doi.org/10.1158/1078-0432.CCR-23-2589
Published: 15 March 2024
View article titled, Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA
Open the PDF for Early Detection of Molecular Residual Disease and Risk Stratification for Children with Acute Myeloid Leukemia via Circulating Tumor DNA in another window
Includes: Supplementary data
Journal Articles

CD46-Targeted Theranostics for PET and 225Ac-Radiopharmaceutical Therapy of Multiple Myeloma

Anju Wadhwa, Sinan Wang, Bonell Patiño-Escobar, Anil P. Bidkar, Kondapa Naidu Bobba, Emily Chan, Niranjan Meher, Scott Bidlingmaier, Yang Su, Suchi Dhrona, Huimin Geng, Vishesh Sarin, Henry F. VanBrocklin, David M. Wilson, Jiang He, Li Zhang, Veronica Steri, Sandy W. Wong, Thomas G. Martin, Youngho Seo, Bin Liu, Arun P. Wiita, Robert R. Flavell
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (5): 1009–1021.
https://doi.org/10.1158/1078-0432.CCR-23-2130
Published: 01 March 2024
View article titled, CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma
Open the PDF for CD46-Targeted Theranostics for PET and <sup>225</sup>Ac-Radiopharmaceutical Therapy of Multiple Myeloma in another window
Includes: Supplementary data
Journal Articles

Treatment of Prostate Cancer with CD46-targeted 225Ac Alpha Particle Radioimmunotherapy

Anil P. Bidkar, Sinan Wang, Kondapa Naidu Bobba, Emily Chan, Scott Bidlingmaier, Emily A. Egusa, Robin Peter, Umama Ali, Niranjan Meher, Anju Wadhwa, Suchi Dhrona, Chandrashekhar Dasari, Denis Beckford-Vera, Yang Su, Ryan Tang, Li Zhang, Jiang He, David M. Wilson, Rahul Aggarwal, Henry F. VanBrocklin, Youngho Seo, Jonathan Chou, Bin Liu, Robert R. Flavell
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (10): 1916–1928.
https://doi.org/10.1158/1078-0432.CCR-22-3291
Published: 15 May 2023
View article titled, Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy
Open the PDF for Treatment of Prostate Cancer with CD46-targeted <sup>225</sup>Ac Alpha Particle Radioimmunotherapy in another window
Includes: Supplementary data
Journal Articles

The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial

Tingyu Wang, Xiuhua Sun, Lihua Qiu, Hang Su, Junning Cao, Zhiming Li, Yuqin Song, Li Zhang, Dengju Li, Huijing Wu, Wei Zhang, Junmin Li, Keshu Zhou, Hui Zhou, Yu Yang, Zhifeng Li, Hong Cen, Zhen Cai, Zhihui Zhang, Weijun Fu, Jie Jin, Fei Li, Weixin Wu, Xuekui Gu, Weiliang Zhu, Lihong Liu, Zengjun Li, Shuhua Yi, Hanying Bao, Zusheng Xu, Lugui Qiu
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1440–1449.
https://doi.org/10.1158/1078-0432.CCR-22-2939
Published: 14 April 2023
View article titled, The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial
Open the PDF for The Oral PI3Kδ Inhibitor Linperlisib for the Treatment of Relapsed and/or Refractory Follicular Lymphoma: A Phase II, Single-Arm, Open-Label Clinical Trial in another window
Includes: Supplementary data
Journal Articles

FOXM1 Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer

Shaoxing Guan, Xi Chen, Youhao Chen, Wen Xie, Heng Liang, Xia Zhu, Yunpeng Yang, Wenfeng Fang, Yan Huang, Hongyun Zhao, Wei Zhuang, Shu Liu, Min Huang, Xueding Wang, Li Zhang
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (17): 3770–3784.
https://doi.org/10.1158/1078-0432.CCR-22-0791
Published: 01 September 2022
View article titled, <em>FOXM1</em> Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer
Open the PDF for <em>FOXM1</em> Variant Contributes to Gefitinib Resistance via Activating Wnt/β-Catenin Signal Pathway in Patients with Non–Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease

Ning Zhao, Shalini Chopra, Kai Trepka, Yung-Hua Wang, Sasank Sakhamuri, Nima Hooshdaran, Hyunjung Kim, Jie Zhou, Shion A. Lim, Kevin K. Leung, Emily A. Egusa, Jun Zhu, Li Zhang, Adam Foye, Renuka Sriram, Emily Chan, Youngho Seo, Felix Y. Feng, Eric J. Small, Jonathan Chou, James A. Wells, Rahul Aggarwal, Michael J. Evans
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (14): 3066–3075.
https://doi.org/10.1158/1078-0432.CCR-21-3858
Published: 15 July 2022
View article titled, CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease
Open the PDF for CUB Domain-Containing Protein 1 (CDCP1) Is a Target for Radioligand Therapy in Castration-Resistant Prostate Cancer, including PSMA Null Disease in another window
Includes: Supplementary data
Journal Articles

Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma

Virginia Aragon-Sanabria, Anusha Aditya, Li Zhang, Feng Chen, Barney Yoo, Tianye Cao, Brian Madajewski, Rachel Lee, Melik Z. Turker, Kai Ma, Sebastien Monette, Peiming Chen, Jing Wu, Shutian Ruan, Michael Overholtzer, Pat Zanzonico, Charles M. Rudin, Cameron Brennan, Ulrich Wiesner, Michelle S. Bradbury
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2938–2952.
https://doi.org/10.1158/1078-0432.CCR-21-4053
Published: 01 July 2022
View article titled, Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma
Open the PDF for Ultrasmall Nanoparticle Delivery of Doxorubicin Improves Therapeutic Index for High-Grade Glioma in another window
Includes: Supplementary data
Journal Articles

A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence Friedlander, Lawrence Fong, Pamela L. Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul Aggarwal
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1531–1539.
https://doi.org/10.1158/1078-0432.CCR-21-4302
Published: 14 April 2022
View article titled, A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer
Open the PDF for A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study

Qing Zhou, Lin Wu, Pei Hu, Tongtong An, Jianying Zhou, Li Zhang, Xiao-Qing Liu, Feng Luo, Xin Zheng, Ying Cheng, Nong Yang, Junling Li, Jifeng Feng, Baohui Han, Yong Song, Kai Wang, Li Zhang, Jian Fang, Hong Zhao, Yongqian Shu, Xiao-Yan Lin, Zhihong Chen, Bin Gan, Wan-Hong Xu, Wei Tang, Xiaoying Zhang, Jin-Ji Yang, Xiao Xu, Yi-Long Wu
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (6): 1127–1135.
https://doi.org/10.1158/1078-0432.CCR-21-2595
Published: 15 March 2022
View article titled, A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study
Open the PDF for A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non–Small Cell Lung Cancer: a Multicenter Phase I/II Study in another window
Includes: Supplementary data
Journal Articles

Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, Roger K-C Ngan, Arunee Dechaphunkul, Li Zhang, Chia-Jui Yen, Po Chung Chan, Somvilai Chakrabandhu, Brigette B.Y. Ma, Suebpong Tanasanvimon, Victor H.F. Lee, Pei-Jen Lou, Zujun Li, Alexander I. Spira, Ammar Sukari, Joël Guigay, Steven McCune, Juan Gonzalez-Maffe, Sebastian Szpakowski, Yao Yao, Hongzi Liang, Jennifer Mataraza, Romain Séchaud, Luigi Manenti, Darren W-T. Lim
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (23): 6413–6423.
https://doi.org/10.1158/1078-0432.CCR-21-0822
Published: 01 December 2021
View article titled, Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer
Open the PDF for Phase II, Randomized Study of Spartalizumab (PDR001), an Anti–PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer in another window
Includes: Supplementary data
Journal Articles

Abstract PO-008: Mechanistic and therapeutic links between purine biosynthesis and DNA damage in glioblastoma

Andrew J. Scott, Weihua Zhou, Kari Wilder-Romans, Anthony C. Andren, Li Zhang, Yoshie Umemura, Nathan Qi, Theodore S. Lawrence, Costas A. Lyssiotis, Daniel R Wahl
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (8_Supplement): PO-008.
https://doi.org/10.1158/1557-3265.RADSCI21-PO-008
Published: 15 April 2021
View article titled, Abstract PO-008: Mechanistic and therapeutic links between purine biosynthesis and DNA damage in glioblastoma
Journal Articles

Abstract PO011: Spatial immune cell and transcriptome profiling uncover differential cellular and molecular signatures in primary and metastatic tumor sites in patients with advanced uterine serous cancer

Li Zhang, Angela Rynne-Vidal, Karen H. Lu, Samuel C. Mok
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (3_Supplement): PO011.
https://doi.org/10.1158/1557-3265.ENDOMET20-PO011
Published: 01 February 2021
View article titled, Abstract PO011: Spatial immune cell and transcriptome profiling uncover differential cellular and molecular signatures in primary and metastatic tumor sites in patients with advanced uterine serous cancer
Journal Articles

Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study

Li Zhang, Li Meng, Bingcheng Liu, Yanli Zhang, Huanling Zhu, Jiuwei Cui, Aining Sun, Yu Hu, Jie Jin, Hao Jiang, Xi Zhang, Yan Li, Li Liu, Wanggang Zhang, Xiaoli Liu, Jian Gu, Jianhui Qiao, Guifang Ouyang, Xin Liu, Jianmin Luo, Ming Jiang, Xiaobao Xie, Jianyong Li, Chunting Zhao, Mei Zhang, Tonghua Yang, Jianxiang Wang
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (1): 70–77.
https://doi.org/10.1158/1078-0432.CCR-20-1600
Published: 04 January 2021
View article titled, Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study
Open the PDF for Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study in another window
Includes: Supplementary data
Journal Articles

Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics

Brian Madajewski, Feng Chen, Barney Yoo, Melik Z. Turker, Kai Ma, Li Zhang, Pei-Ming Chen, Rupa Juthani, Virginia Aragon-Sanabria, Mithat Gonen, Charles M. Rudin, Ulrich Wiesner, Michelle S. Bradbury, Cameron Brennan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (20): 5424–5437.
https://doi.org/10.1158/1078-0432.CCR-20-0851
Published: 15 October 2020
View article titled, Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics
Open the PDF for Molecular Engineering of Ultrasmall Silica Nanoparticle–Drug Conjugates as Lung Cancer Therapeutics in another window
Includes: Supplementary data
Journal Articles

Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial

Xi Li, Li Zhang, Da Jiang, Yan Wang, Aimin Zang, Cuimin Ding, Min Zhao, Wuyun Su, Yan Zhang, Diansheng Zhong, Jin Wu, Cuiying Zhang, Guangyu An, Xingsheng Hu, Gang Cheng, Huaqing Wang, Yongqun Li, Xiaohui He, Junli Liu, Li Liang, Lieming Ding, Li Mao, Shucai Zhang
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (13): 3162–3171.
https://doi.org/10.1158/1078-0432.CCR-19-3064
Published: 01 July 2020
View article titled, Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial
Open the PDF for Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial in another window
Includes: Supplementary data
Journal Articles

Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model

Rupa Juthani, Brian Madajewski, Barney Yoo, Li Zhang, Pei-Ming Chen, Feng Chen, Melik Z. Turker, Kai Ma, Michael Overholtzer, Valerie A. Longo, Sean Carlin, Virginia Aragon-Sanabria, Jason Huse, Mithat Gonen, Pat Zanzonico, Charles M. Rudin, Ulrich Wiesner, Michelle S. Bradbury, Cameron W. Brennan
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 147–158.
https://doi.org/10.1158/1078-0432.CCR-19-1834
Published: 03 January 2020
View article titled, Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model
Open the PDF for Ultrasmall Core-Shell Silica Nanoparticles for Precision Drug Delivery in a High-Grade Malignant Brain Tumor Model in another window
Includes: Multimedia, Supplementary data
Journal Articles

Leukotriene Synthesis Is Critical for Medulloblastoma Progression

Fang Du, Larra Yuelling, Eric H. Lee, Yuan Wang, Shengyou Liao, Yan Cheng, Li Zhang, Chaonan Zheng, Suraj Peri, Kathy Q. Cai, Jessica M.Y. Ng, Tom Curran, Peng Li, Zeng-jie Yang
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (21): 6475–6486.
https://doi.org/10.1158/1078-0432.CCR-18-3549
Published: 01 November 2019
View article titled, Leukotriene Synthesis Is Critical for Medulloblastoma Progression
Open the PDF for Leukotriene Synthesis Is Critical for Medulloblastoma Progression in another window
Includes: Supplementary data